1. First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis. (10th January 2017) Authors: Glatt, Sophie; Helmer, Eric; Haier, Birgit; Strimenopoulou, Foteini; Price, Graham; Vajjah, Pavan; Harari, Olivier A.; Lambert, John; Shaw, Stevan Journal: British journal of clinical pharmacology Issue: Volume 83:Number 5(2017:May) Page Start: 991 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗